Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$34.45M+8622.53%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Silviu Itescu
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 108
- Beta
- 0.81
- Country
- AU
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 3.54
Financials
Revenue
$34.45M+8622.5%Net Income
$-8.67MEBITDA
$-9.97MFree Cash Flow
$-6.95MEPS (diluted)
$-0.07Shares Outstanding (diluted)
129.77M+141.4%Operating Expenses
$40.08MCash & Debt
$102.91MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $120.79M | $-57.76M | $-0.45 |
| 2025 | $17.20M | $-102.14M | $-0.84 |
| 2024 | $5.90M | $-87.96M | $-0.89 |
| 2023 | $7.50M | $-81.89M | $-0.98 |
| 2022 | $10.21M | $-91.35M | $-1.30 |
| 2021 | $7.46M | $-98.81M | $-1.60 |
| 2020 | $32.16M | $-77.94M | $-1.50 |
| 2019 | $16.72M | $-89.80M | $-1.80 |
| 2018 | $17.34M | $-35.29M | $-0.76 |
| 2017 | $2.41M | $-76.81M | $-1.40 |
| 2016 | $42.55M | $-4.13M | $-0.08 |
| 2015 | $23.75M | $-119.37M | $-2.20 |
| 2014 | $25.98M | $-80.96M | $-1.50 |
| 2013 | $28.79M | $-61.66M | $-1.10 |
Valuation
MESOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-85.71%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·12d ago·Negative
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the United States Food and Drug Administration (FDA) to implement a new potency assay, T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of all new commercial p…
View source ↗ - Newsseekingalpha.com·40d ago·Positive
Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·40d ago·Positive
… Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of U…
View source ↗ - Newsmarketbeat.com·40d ago·Neutral
Mesoblast H2 Earnings Call Highlights Mesoblast NASDAQ: MESO reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company's FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD.
View source ↗ - Newszacks.com·48d ago·Neutral
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.
View source ↗ - Newsbenzinga.com·49d ago·Neutral
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment Mesoblast Limited (NASDAQ:MESO) stock is trading higher on Monday after the company concluded patient dosing for its crucial Phase 3 clinical trial evaluating rexlemestrocel-L.
View source ↗ - Newsglobenewswire.com·50d ago·Positive
…Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with the inflammatory condition of degenerative disc disease. T…
View source ↗
Earnings
Thu, Mar 4(in 5 months)
Consensus estimate $-0.15 per share
Typical surprise -23.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 26$-0.13 vs $-0.11miss
- Thu, Apr 30$-0.07 vs $-0.08beat
- Thu, Feb 26$-0.31 vs $-0.24miss
- Thu, Aug 28$-0.32 vs $-0.20miss
- Tue, Jul 29$-0.43 vs $-0.37miss
- Wed, Apr 30$-0.21 vs $-0.35beat
Estimates and results for MESO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MESO officers and directors.
- Bought
- $19.9m
- Sold
- —
26 trades
0 trades
- George Gregorybought
- George Gregorybought
- George Gregorybought
- George Gregorybought
- George Gregorybought
- George Gregorybought
- George Gregorybought
- George Gregorybought
53 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MESO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.